Coherus Oncology, Inc. (CHRS) SEC Filings & Earnings Calls

Dilution risk from potential issuance of up to $50M in common stock via ATM offering.

“may offer and sell ... shares ... having an aggregate offering price of up to $50.0 million”

New debt agreement may have different terms; no details on amounts or covenants provided.

“Loan and Security Agreement, dated August 12, 2026, by and among the Company... Innovatus Life Sciences Lending Fund I, LP” · word for word

CVR payments depend on future asset sales or royalties; no guaranteed value.

“contingent value rights representing the right to receive payments from the Company in the event that the Company sells, grants a license...” · word for word

Going concern risk due to cash burn

“The Company does not expect its existing cash, cash equivalents and marketable securities to be sufficient to fund the completion of its clinical trials through commercialization and will need additional funding to support its continuing operations.” · word for word

Dependence on single product LOQTORZI

“We currently have only one approved and marketed product, and we have multiple product candidates that are not approved and still in development.” · word for word

Cash burn continues; cash decreased from $172.1M to $105.3M since year-end.

“Cash, cash equivalents and marketable securities totaled $105.3 million as of June 30, 2026, compared to $172.1 million as of December 31, 2025.” · word for word

Dependence on single product LOQTORZI for revenue.

“LOQTORZI net revenue of $13.6 million represents 95% of total revenue.” · word for word

Remediated material weakness in internal control over financial reporting related to inventory reconciliations.

“Material weakness reported in FY2024 10-K, remediated as of FY2025 10-K.”

Limited product diversification

“We have a limited history of profitability, which we have not maintained and may not achieve again, and only one product that has been approved and marketed and with multiple product candidates that are not approved and still in development.” · word for word

Competition from other immuno-oncology biologics

“Our product LOQTORZI faces, and our product candidates tagmokitug and casdozokitug, if approved, will face, significant competition from other immuno-oncology biologics and other treatment regimens.” · word for word

Regulatory and healthcare reform pressure

“Healthcare reform measures, including the Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (the OBBBA), may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product, affect the prices we may set, and have a material adverse effect on our business and results of operations.” · word for word

Manufacturing and supply chain risks

“We are subject to a multitude of manufacturing risks and the risks of inaccurately forecasting sales of our product. Any adverse developments affecting the manufacturing operations of our product and product candidates, including the risks associated with transitioning our biomanufacturing processes from an offshoring business model to an onshoring business ” · word for word

Dependence on key executives

“We are highly dependent on the services of our key executives and personnel, including our President and Chief Executive Officer, Dennis M. Lanfear, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.” · word for word

Revenue concentration on single product LOQTORZI and weather-related seasonality risk.

“LOQTORZI revenue decreased 5% sequentially due to severe weather events and seasonality.”

Continued net losses and reliance on equity financing for cash runway.

“Net loss of $36.9M; raised $53.6M via equity offering in Q1.”

Severe stock option underwater risk and retention failure

“The Board was concerned that adverse changes in the market price of our common stock since the Eligible Options were granted could materially interfere with the Company’s efforts to retain the service of the holders of the Eligible Options.” · word for word

Significant shareholder dilution from equity plan increase

“an additional 7,700,000 shares of common stock have been reserved for issuance under the 2014 Plan over the existing share reserve” · word for word

Business development execution failure

“Business Development 10% 0%” · word for word

Dependence on LOQTORZI for revenue; pipeline risk

“LOQTORZI remains the only FDA-approved and available treatment in the U.S. for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC). Pipeline candidates still in early stages.” · word for word

Equity dilution from recent financings

“In October 2025, the Company sold 4,634,995 shares of common stock and warrants... In February 2026, Coherus sold 28,600,000 shares of its common stock in public offering for proceeds of approximately $47.0 million.” · word for word

Inflation and margin pressure

“Continuing increases in inflation could impact the overall demand for our product, our costs for labor and materials and the size of any margins we are able to realize on our revenues.” · word for word

Cybersecurity risk

“Our information technology systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches and geopolitical tensions or conflicts... may create a heightened risk of cyberattacks.” · word for word

Dilution risk: 28.6M shares issued at $1.75, representing substantial dilution to existing shareholders.

“Issued 28.6M shares; pre-offer shares not stated but likely significant dilution.”

Market signal: equity offering at low price suggests capital needs and potential distress.

“Offering price $1.75; net proceeds $47M; biotech company raising capital.”

Clinical trial risk; early-stage study may fail to meet endpoints.

“Phase 1b clinical study in mCRPC; no efficacy data yet.”

Dilution risk from equity offering

“At-the-market offering of up to $64.88M common stock.”

Pipeline dependency on clinical trial outcomes for Tagmokitug and Casdozokitug; revenue concentration on LOQTORZI.

“Tagmokitug anti-CCR8 cytolytic antibody; Casdozokitug IL-27 antagonist; LOQTORZI projected to reach $150-200M by 2028” · word for word

Divestiture of biosimilar businesses represents strategic shift; ongoing operations now focused on remaining business.

“UDENYCA Sale represented the last and most significant divestiture of the Company’s biosimilar businesses.” · word for word

Dependence on LOQTORZI for near-term revenue; pipeline still in clinical stages.

“Only FDA-approved product is LOQTORZI; pipeline data readouts not until 2026.”

Cash burn from R&D and clinical trials.

“Cash position $191.7M; no profitability disclosed.”

Single product dependency

“We have a limited history of profitability, which we have not maintained and may not achieve again, and only one product that has been approved and marketed and with multiple product candidates that are not approved and still in development.” · word for word

Revenue concentration risk after UDENYCA divestiture

“UDENYCA was our largest product that contributed significantly more revenue to our business than LOQTORZI currently.” · word for word

Dependence on third-party manufacturer and supplier

“We rely on third parties, and in some cases a single third party, to manufacture nonclinical, clinical and commercial drug supplies of our product and product candidates and to store critical components of our product and product candidates for us.” · word for word